Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes

References

• Azziz R , Woods KS , Reyna R , et al . The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9.
   PubMed Web of Science ®Google Scholar
• Yildiz BO , Bozdag G , Yapici Z , et al . Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27:3067–73.
   PubMed Web of Science ®Google Scholar
• Boyle JA , Cunningham J , O’Dea K , et al . Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust 2012;196:62–6.
   PubMed Web of Science ®Google Scholar
• Ma Y , Li R , Qiao J , et al . Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Chin Med J 2010;123:2185–9.
   PubMed Web of Science ®Google Scholar
• ESHRE Capri Workshop Group . Health and fertility in World Health Organization group 2 anovulatory women. Hum Reprod Update 2012;18:586–99.
   PubMed Web of Science ®Google Scholar
• Brown J , Farquhar C , Beck J , et al . Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009;4:CD002249.
   Google Scholar
• Nastri CO , Ferriani RA , Rocha IA , Martins WP. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 2010;27:121–8.
   PubMed Web of Science ®Google Scholar
• Baumgarten M , Polanski L , Campbell B , Raine-Fenning N. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis. Hum Fertil (Camb) 2013;16:168–74.
   PubMed Web of Science ®Google Scholar
• Kumar P , Nawani N , Malhotra N , et al . Assisted reproduction in polycystic ovarian disease: a multicentric trial in India. J Hum Reprod Sci 2013;6:49–53.
   PubMedGoogle Scholar
• Siristatidis CS , Vrachnis N , Creatsa M , et al . In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev 2013;10:CD006606.
   PubMed Web of Science ®Google Scholar
• Coffler MS , Patel K , Dahan MH , et al . Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:1742–7.
   PubMed Web of Science ®Google Scholar
• Coffler MS , Patel K , Dahan MH , et al . Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003;88:5624–31.
   PubMed Web of Science ®Google Scholar
• Doronzo G , Russo I , Mattiello L , et al . Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. Eur J Clin Invest 2004;34:664–73.
   PubMed Web of Science ®Google Scholar
• Jayaprakasan K , Chan Y , Islam R , et al . Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril 2012;98:657–63.
   PubMed Web of Science ®Google Scholar
• Ocal P , Sahmay S , Cetin M , et al . Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 2011;28:1197–203.
   PubMed Web of Science ®Google Scholar
• Kollmann M , Martins WP , Lima MLS , et al . Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2016;48:709–18.
   PubMed Web of Science ®Google Scholar
• Zawadski JK , Dunaif A. Diagnostic criteria for polycystic ovary syndrome: toward a rational approach. In: Dunaif A , Givens JR , Haseltine FP , Merriam GR , eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications; 1992:377–84.
   Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7.
   PubMed Web of Science ®Google Scholar
• Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781–5.
   PubMed Web of Science ®Google Scholar
• Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006;91:786–9.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health . Evidence-based methodology workshop on polycystic ovary syndrome, December 3–5, 2012. Executive summary. Available from: https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf [last accessed 1 March 2016].
   Google Scholar
• Cooper TG , Noonan E , von Eckardstein S , et al . World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010;16:231–45.
   PubMed Web of Science ®Google Scholar
• Artini PG , Fasciani A , Monti M , et al . Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril 1998;70:560–4.
   PubMed Web of Science ®Google Scholar
• Dosouto C , Haahr T , Humaidan P. Gonadotropin-releasing hormone agonist (GnRHa) trigger – state of the art. Reprod Biol 2017;17:1–8.
   PubMed Web of Science ®Google Scholar
• Ramezanali F , Ashrafi M , Hemat M , et al . Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-Müllerian hormone. Reprod Biomed Online 2016;32:503–12.
   PubMed Web of Science ®Google Scholar
• Desforges-Bullet V , Gallo C , Lefebvre C , et al . Increased anti-Müllerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization. Fertil Steril 2010;94:198–204.
   PubMed Web of Science ®Google Scholar
• Blank SK , McCartney CR , Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update 2006;12:351–61.
   PubMed Web of Science ®Google Scholar
• Romualdi D , Di Florio C , Tagliaferri V , et al . The role of anti-Müllerian hormone in the characterization of the different polycystic ovary syndrome phenotypes. Reprod Sci 2016;23:655–61.
   PubMed Web of Science ®Google Scholar
• Sahmay S , Atakul N , Oncul M , et al . Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013;170:157–61.
   PubMed Web of Science ®Google Scholar
• Laven JSE , Mulders AGMGJ , Visser JA , et al . Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318–23.
   PubMed Web of Science ®Google Scholar
• Broekmans FJ , Visser JA , Laven JSE , et al . Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol Metab 2008;19:340–7.
   PubMed Web of Science ®Google Scholar
• Jamil AS , Alalaf SK , Al-Tawil NG , Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet 2016;293:447–56.
   PubMed Web of Science ®Google Scholar
• Piouka A , Farmakiotis D , Katsikis I , et al . Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296:E238–43.
   PubMed Web of Science ®Google Scholar
• Dewailly D , Catteau-Jonard S , Reyss A-C , et al . Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 2006;91:3922–7.
   PubMed Web of Science ®Google Scholar
• Panidis D , Tziomalos K , Misichronis G , et al . Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2012;27:541–9.
   PubMed Web of Science ®Google Scholar
• Dilbaz B , Ozkaya E , Cinar M , et al . Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 2011;39:272–7.
   PubMed Web of Science ®Google Scholar
• Guastella E , Longo RA , Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010;94:2197–201.
   PubMed Web of Science ®Google Scholar
• Yilmaz M , Isaoglu U , Delibas IB , Kadanali S. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res 2011;37:1020–6.
   PubMed Web of Science ®Google Scholar
• Katsikis I , Karkanaki A , Misichronis G , et al . Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;156:181–5.
   PubMed Web of Science ®Google Scholar
• Humaidan P , Ejdrup Bredkjær H , Bungum L , et al . GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005;20:1213–20.
   PubMed Web of Science ®Google Scholar
• Humaidan P , Polyzos NP , Alsbjerg B , et al . GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013;28:2511–21.
   PubMed Web of Science ®Google Scholar
• Humaidan P , Bredkjær HE , Westergaard LG , Andersen CY. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010;93:847–54.
   PubMed Web of Science ®Google Scholar
• Oktay K , Türkçüoğlu I , Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010;20:783–8.
   PubMed Web of Science ®Google Scholar
• Lok F , Pritchard J , Lashen H. Successful treatment of empty follicle syndrome by triggering endogenous LH surge using GnRH agonist in an antagonist down-regulated IVF cycle. Hum Reprod 2003;18:2079–81.
   PubMed Web of Science ®Google Scholar